Seventy-three patients were included in the study; 35 were randomized to treatment with the active-treatment insert and the remainder to the placebo insert. The insertion process was not successful in 1 patient in the dexamethasone insert group. Two patients (1 in each group) withdrew consent and did not complete the study.
Dr. Feulner reported that the dexamethasone insert was superior to vehicle for treating ocular itching on day 8, and the responses were significant (P < 0.0001) compared with the placebo group at 3, 5, and 7 minutes after CAC. The treatment differences for the dexamethasone insert were -1.02, -0.87, and -1.04, respectively, at the 3 time points.